0000899243-20-006973.txt : 20200304 0000899243-20-006973.hdr.sgml : 20200304 20200304172716 ACCESSION NUMBER: 0000899243-20-006973 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200103 FILED AS OF DATE: 20200304 DATE AS OF CHANGE: 20200304 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHIERMEIER ANDREW CENTRAL INDEX KEY: 0001738456 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37766 FILM NUMBER: 20688455 MAIL ADDRESS: STREET 1: C/O INTELLIA THERAPEUTICS STREET 2: 40 ERIE STREET STE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intellia Therapeutics, Inc. CENTRAL INDEX KEY: 0001652130 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 364785571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-285-6200 MAIL ADDRESS: STREET 1: 40 ERIE STREET STREET 2: SUITE 130 CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-03 0 0001652130 Intellia Therapeutics, Inc. NTLA 0001738456 SCHIERMEIER ANDREW C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139 0 1 0 0 EVP, Chief Operating Officer Common Stock 10316 D Stock Option (Right to Buy) 13.48 2020-01-03 4 A 0 15000 0.00 A 2020-01-03 2027-01-02 Common Stock 15000 15000 D Stock Option (Right to Buy) 13.40 2020-03-02 4 A 0 135000 0.00 A 2030-03-01 Common Stock 135000 135000 D This amount includes 1,672 shares acquired under the NTLA Employee Stock Purchase Plan (912 shares purchased on 6/30/2019 and 760 shares purchased on 12/31/2019). On January 3, 2017, the reporting person was granted an option to purchase 15,000 shares of common stock. The option vested based on the satisfaction of certain performance criteria. The performance criteria was met, resulting in the vesting of option as to 15,000 shares. This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter. /s/ Jose E. Rivera, Attorney-In-Fact 2020-03-04